This antimyeloma effect of pomalidomide has been reported, including induction of antiproliferative and proapoptotic effects on MM cells (19, 20), and modulation of BM microenvironment to inhibit the binding of MM cells to BM stromal cells that mediate the production of growth factors and angiogenic molecules, including vascular endothelial growth factor (VEGF) (21). The gene discussed is VEGFA; the disease is Miyoshi myopathy.